Takamasa Nukui1, Atsushi Matsui2, Hideki Niimi2, Tomoyuki Sugimoto3, Tomohiro Hayashi1, Nobuhiro Dougu1, Hirofumi Konishi1, Mamoru Yamamoto1, Ryoko Anada1, Noriyuki Matsuda1, Isao Kitajima2, Yuji Nakatsuji4. 1. Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. 2. Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. 3. Faculty of Data Science, Graduate School of Data Science, University of Shiga, 1-1-1 Banba Hikone, Shiga, 522-8522, Japan. 4. Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. nakatsuj@med.u-toyama.ac.jp.
Abstract
BACKGROUND: Extracellular adenosine 5'-triphosphate (ATP) has been suggested to cause neuroinflammation and motor neuron degeneration by activating microglia and astrocytes in amyotrophic lateral sclerosis (ALS). Since we have developed a highly sensitive ATP assay system, we examined cerebrospinal fluid (CSF) ATP levels in patients with ALS whether it can be a useful biomarker in ALS. METHODS: Forty-eight CSF samples from 44 patients with ALS were assayed for ATP with a newly established, highly sensitive assay system using luciferase luminous reaction. CSF samples from patients with idiopathic normal pressure hydrocephalus (iNPH) were assayed as a control. Patients were divided into two groups depending on their disease severity, as evaluated using the Medical Research Council (MRC) sum score. Correlations between the CSF ATP levels and other factors, including clinical data and serum creatinine levels, were evaluated. RESULTS: CSF ATP levels were significantly higher in patients with ALS than in the iNPH (716 ± 411 vs. 3635 ± 5465 pmol/L, p < 0.01). CSF ATP levels were significantly higher in the more severe group than in the iNPH group (6860 ± 8312 vs. 716 ± 411 pmol/L, p < 0.05) and mild group (6860 ± 8312 vs. 2676 ± 3959 pmol/L, p < 0.05) respectively. ALS functional rating scale-revised (ALSFRS-R) (37.9 ± 5.7 vs. 42.4 ± 2.8, p < 0.01) and serum creatinine levels (0.51 ± 0.13 vs. 0.68 ± 0.23 mg/dL, p < 0.05) were significantly lower in the severe group than in the mild group respectively. A negative correlation of CSF ATP levels with MRC sum score was demonstrated in the correlation analysis adjusted for age and sex (r = -0.3, p = 0.08). CONCLUSIONS: Extracellular ATP is particularly increased in the CSF of patients with advanced ALS. CSF ATP levels may be a useful biomarker for evaluating disease severity in patients with ALS.
BACKGROUND: Extracellular adenosine 5'-triphosphate (ATP) has been suggested to cause neuroinflammation and motor neuron degeneration by activating microglia and astrocytes in amyotrophic lateral sclerosis (ALS). Since we have developed a highly sensitive ATP assay system, we examined cerebrospinal fluid (CSF) ATP levels in patients with ALS whether it can be a useful biomarker in ALS. METHODS: Forty-eight CSF samples from 44 patients with ALS were assayed for ATP with a newly established, highly sensitive assay system using luciferase luminous reaction. CSF samples from patients with idiopathic normal pressure hydrocephalus (iNPH) were assayed as a control. Patients were divided into two groups depending on their disease severity, as evaluated using the Medical Research Council (MRC) sum score. Correlations between the CSF ATP levels and other factors, including clinical data and serum creatinine levels, were evaluated. RESULTS: CSF ATP levels were significantly higher in patients with ALS than in the iNPH (716 ± 411 vs. 3635 ± 5465 pmol/L, p < 0.01). CSF ATP levels were significantly higher in the more severe group than in the iNPH group (6860 ± 8312 vs. 716 ± 411 pmol/L, p < 0.05) and mild group (6860 ± 8312 vs. 2676 ± 3959 pmol/L, p < 0.05) respectively. ALS functional rating scale-revised (ALSFRS-R) (37.9 ± 5.7 vs. 42.4 ± 2.8, p < 0.01) and serum creatinine levels (0.51 ± 0.13 vs. 0.68 ± 0.23 mg/dL, p < 0.05) were significantly lower in the severe group than in the mild group respectively. A negative correlation of CSF ATP levels with MRC sum score was demonstrated in the correlation analysis adjusted for age and sex (r = -0.3, p = 0.08). CONCLUSIONS: Extracellular ATP is particularly increased in the CSF of patients with advanced ALS. CSF ATP levels may be a useful biomarker for evaluating disease severity in patients with ALS.
Authors: Juan Ignacio Diaz-Hernandez; Rosa Gomez-Villafuertes; Miriam León-Otegui; Lourdes Hontecillas-Prieto; Ana Del Puerto; Jose Luis Trejo; Jose Javier Lucas; Juan Jose Garrido; Javier Gualix; Maria Teresa Miras-Portugal; Miguel Diaz-Hernandez Journal: Neurobiol Aging Date: 2011-11-01 Impact factor: 4.673
Authors: Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee Journal: Science Date: 2006-10-06 Impact factor: 47.728
Authors: F Patin; P Corcia; B Madji Hounoum; C Veyrat-Durebex; E Respaud; E Piver; I Benz-de Bretagne; P Vourc'h; C R Andres; H Blasco Journal: Eur J Neurol Date: 2015-06-22 Impact factor: 6.089
Authors: D Keizman; M Ish-Shalom; S Berliner; N Maimon; Y Vered; I Artamonov; J Tsehori; B Nefussy; V E Drory Journal: J Neurol Sci Date: 2009-06-24 Impact factor: 3.181
Authors: Ruben P A van Eijk; Marinus J C Eijkemans; Toby A Ferguson; Stavros Nikolakopoulos; Jan H Veldink; Leonard H van den Berg Journal: J Neurol Neurosurg Psychiatry Date: 2017-10-30 Impact factor: 10.154